Evidence map›Paper›PMID 32244277›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Seitaro Nakagawa, Greg G Hillebrand, Gabriel Nunez

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Article
  3. Prevention and Treatment ofPathogens (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Review
  6. Dysbiosis in the Pathogenesis of Atopic Dermatitis.The Journal of dermatology · 2026
    Review
  7. Review
  8. Review
  9. Tackling Drug Resistance and Virulence inThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  10. Review
  11. Article
  12. DisarmingPathogens (Basel, Switzerland) · 2025
    Review
  13. Review
  14. Structural characteristics, functions, and counteracting strategies of biofilms inComputational and structural biotechnology journal · 2025
    Review
  15. Skin Microbiome in Health and Disease: Mechanisms and Emerging Therapeutic Strategies.Clinical, cosmetic and investigational dermatology · 2025
    Review
  16. Antibacterial efficacy of carnosic acid as an intracanal medicament againstJournal of conservative dentistry and endodontics · 2024
    Article
  17. Article
  18. Antimicrobial and Antibiofilm Potential ofPlants (Basel, Switzerland) · 2024
    Article
  19. Review
  20. Anti-Biofilm Activity of Carnosic Acid fromPlants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Seitaro NakagawaDepartment of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Greg G HillebrandDepartment of Innovation and Science, Amway Corporation, Ada, MI 49355, USA.
Gabriel NunezDepartment of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
University of Michigan–Ann Arbor · USAmway (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

agranti-virulence therapyatopic dermatitisquorum sensing inhibitionskin microbiomeStaphylococcus aureus

Identifiers

PMID32244277
PMCPMC7235817
OpenAlexW3013554291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.